Compare Gilead Sciences, Inc. (GILD) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NextEra Energy, Inc. — how do they compare? Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B), while NextEra Energy, Inc. trades at $77.46 (market cap $160.75B). The key difference: Gilead Sciences, Inc. and NextEra Energy, Inc. are close in size by market cap, and NextEra Energy, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and NextEra Energy, Inc. for 83 Days on average.
| GILD | NEE | |
|---|---|---|
Market Cap | $182.09B | $160.75B |
Volume | 4,960,247 | 10,598,021 |
Sector | Health | Utilities |
52-Week High | $155.80 | $97.88 |
52-Week Low | $116.74 | $75.49 |
Typical Hold Time | 111 Days | 83 Days |
Enterprise Value | $205.15B | $268.08B |
Dividend Yield | 2.23% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
NextEra Energy (NEE) trades at $77.37, down 0.65% with a bearish technical signal. The stock shows strong fundamentals with 32.4% net income margin and 17.23% ROE, though recent earnings were mixed with a Q4 miss but Q1-Q2 beats. Analyst consensus remains bullish with 66.7% buy ratings and $96 price target. Recent news highlights growth opportunities including a $22.3 billion energy infrastructure partnership and 18 GW gas development prospects.
NEE presents a compelling long-term investment case with robust profitability and analyst support, though near-term technical weakness and rising debt levels warrant caution. The company's clean energy transition strategy and infrastructure projects provide growth catalysts, but interest rate sensitivity and execution risks on large projects represent key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
